Accuryn key facts
as of Oct 2026- Developer of predictive health monitoring system designed to improve patient care using artificial intelligence and machine insights.
- Accuryn is valued at approximately $111.0M as of Oct 2026 (last reported valuation).
- It has raised $113.2M; the latest was Seed Round ($5.5M) in Sep 2025.
- Notable investors include Ceros..
- Status: Privately Held (backing).
Accuryn's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·Watch Accuryn: the Monday email on marks, rounds and moves
Accuryn funding rounds
No funding rounds for Accuryn are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Accuryn
1Accuryn valuation
Accuryn's last reported valuation was $111 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Accuryn investors
1 investor is on record for Accuryn, including Ceros.. By type, the record holds 1 venture capital firm.
About Accuryn
Developer of predictive health monitoring system designed to improve patient care using artificial intelligence and machine insights. The company's platform provides real-time measurement of intra-abdominal pressure, urine output, and core body temperature in degrees Fahrenheit and degrees Celcius, enabling medical teams to predict adverse outcomes in critical care settings better.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 2011
- Employees
- 37
- Website
- accuryn.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.